CL2008002542A1 - Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. - Google Patents

Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Info

Publication number
CL2008002542A1
CL2008002542A1 CL2008002542A CL2008002542A CL2008002542A1 CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1 CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1
Authority
CL
Chile
Prior art keywords
compounds
pharmaceutical composition
amyloidosis
amyloid
dementia
Prior art date
Application number
CL2008002542A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Mamoru Takaishi
Takeo Sasaki
Yu Yoshida
Toshiyuki Uemura
Takashi Doko
Daisuke Shinmyo
Daiju Hasegawa
Takehiko Miyagawa
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2008002542A1 publication Critical patent/CL2008002542A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS REPRESENTADOSPOR LA FÓRMULA (I-1), O SUS SALES FARMACOLÓGICAMENTE ACEPTABLES, DONDE X1 Y HET SON COMO SE DEFINE EN LAS REIVINDICACIONES. COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHOS COMPUESTOS O SUS SALES FARMACOLÓGICAMENTEACEPTABLES, EN FORMA DE UN INGREDIENTEACTIVO. USO DE DICHA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR UNA ENFERMEDAD CAUSADA POR AMILOIDE-B, TAL COMO ENFERMEDADDE ALZHEIMER, DEMENCIA, SÍNDROME DE DOWN O AMILOIDOSIS.
CL2008002542A 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. CL2008002542A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007225045 2007-08-31
JP2008020009 2008-01-31
JP2008123057 2008-05-09

Publications (1)

Publication Number Publication Date
CL2008002542A1 true CL2008002542A1 (es) 2009-01-02

Family

ID=40387302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002542A CL2008002542A1 (es) 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Country Status (19)

Country Link
US (1) US9453000B2 (es)
EP (2) EP2181992B8 (es)
JP (1) JP5433418B2 (es)
KR (1) KR20100055456A (es)
CN (1) CN101815713B (es)
AR (1) AR068121A1 (es)
AU (1) AU2008292390B2 (es)
BR (1) BRPI0815773A2 (es)
CA (1) CA2694401C (es)
CL (1) CL2008002542A1 (es)
ES (1) ES2529648T3 (es)
IL (1) IL203778A (es)
MX (1) MX2010002098A (es)
MY (1) MY150507A (es)
NZ (1) NZ583515A (es)
PE (1) PE20090674A1 (es)
TW (1) TW200916469A (es)
WO (1) WO2009028588A1 (es)
ZA (1) ZA201000474B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US20090124651A1 (en) * 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
CN102137855A (zh) * 2008-08-27 2011-07-27 卫材R&D管理有限公司 制备某些肉桂酰胺化合物的方法
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
BRPI1007883A2 (pt) * 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US20120165541A1 (en) * 2009-07-31 2012-06-28 Sandoz Ag Method for the preparation of w-amino- alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
US10372396B2 (en) * 2013-02-21 2019-08-06 Lenovo ( Singapore) Pte. Ltd. Discovery and connection to wireless displays
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CN117085022A (zh) * 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
KR20200118005A (ko) * 2018-02-05 2020-10-14 위니베르시떼 드 스트라스부르 통증 치료용 화합물 및 조성물
WO2020163704A1 (en) * 2019-02-07 2020-08-13 Alsatech, Inc. Polyvalent derivatives of emoxypine
AU2023392783A1 (en) * 2022-12-15 2025-06-19 Sitryx Therapeutics Limited Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
CN118459425B (zh) * 2024-04-29 2025-11-14 南通华祥医药科技有限公司 一种吡咯烷-1-胺-二盐酸盐的制备方法
CN121874396B (zh) * 2026-03-20 2026-07-07 余姚市种子种苗管理站 一种鉴别长柄石杉与皱边石杉的分子标记引物组及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) * 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A7 (fi) 1989-05-19 1990-11-20 Eisai Co Ltd Buteenihappojohdannaiset
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
DE69126251T2 (de) 1990-02-08 1997-09-25 Eisai Co Ltd Benzensulfonamidderivat
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
US5804577A (en) * 1995-09-12 1998-09-08 Hoffmann-La Roche Inc. Cephalosporin derivatives
EP0866705A4 (en) 1995-10-19 1999-03-03 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
ATE215950T1 (de) 1996-05-10 2002-04-15 Icos Corp Carbolinderivate
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
RU2189982C2 (ru) 1997-03-31 2002-09-27 Такеда Кемикал Индастриз, Лтд. Азольные соединения, способ их получения, противогрибковая фармацевтическая композиция и способ лечения грибковой инфекции
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
IL131618A0 (en) 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6048678A (en) * 1998-12-28 2000-04-11 Eastman Kodak Company Protective overcoat coating compositions
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
AU2899400A (en) 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
AU2001254555A1 (en) 2000-04-24 2001-11-07 Merck Frosst Canada & Co Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
NZ525917A (en) 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003022273A1 (en) 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
ATE363278T1 (de) 2001-09-14 2007-06-15 Novo Nordisk As Neue liganden für die hisb10 zn2+ stellen des insulin-hexamers in der r-konformation
RU2004118719A (ru) * 2001-11-22 2005-03-27 Оно Фармасьютикал Ко., Лтд. (Jp) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
EP1509505A2 (en) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
AU2003225668A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
JP2005531574A (ja) 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
AU2003247758A1 (en) 2002-06-27 2004-01-19 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
AU2003249937A1 (en) 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
CN1795165A (zh) 2003-04-01 2006-06-28 普拉斯化学品有限公司 无定形辛伐他汀钙及其制备方法
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
WO2005080346A1 (en) 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
WO2005087768A1 (en) 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
EP2261218B1 (en) * 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
US20080261952A1 (en) 2004-08-16 2008-10-23 Jason Bloxham Aryl Urea Derivatives for Treating Obesity
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
CA2628047A1 (en) 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamide derivative
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
TWI386207B (zh) 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
GEP20115139B (en) * 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
WO2009126311A1 (en) * 2008-04-11 2009-10-15 The University Of Texas, M.D. Anderson Cancer Center Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
CN102137855A (zh) 2008-08-27 2011-07-27 卫材R&D管理有限公司 制备某些肉桂酰胺化合物的方法
PT2401256E (pt) 2009-02-26 2013-05-13 Boehringer Ingelheim Int Compostos como antagonistas da bradicinina b1
UY32464A (es) 2009-02-26 2010-09-30 Glaxo Group Ltd Nuevos compuestos de indazol
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JPWO2010098466A1 (ja) 2009-02-27 2012-09-06 Hoya株式会社 成形型およびプラスチックレンズの製造方法
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US8381014B2 (en) * 2010-05-06 2013-02-19 International Business Machines Corporation Node controller first failure error management for a distributed system

Also Published As

Publication number Publication date
TW200916469A (en) 2009-04-16
CA2694401C (en) 2012-12-04
EP2181992A1 (en) 2010-05-05
EP2559693B1 (en) 2014-11-26
CN101815713B (zh) 2013-09-11
JP5433418B2 (ja) 2014-03-05
MX2010002098A (es) 2010-03-30
EP2181992B1 (en) 2013-05-01
NZ583515A (en) 2011-05-27
CA2694401A1 (en) 2009-03-05
US9453000B2 (en) 2016-09-27
BRPI0815773A2 (pt) 2019-09-24
ZA201000474B (en) 2011-05-25
IL203778A (en) 2013-11-28
PE20090674A1 (es) 2009-06-19
ES2529648T3 (es) 2015-02-24
AR068121A1 (es) 2009-11-04
MY150507A (en) 2014-01-30
EP2181992B8 (en) 2013-06-26
WO2009028588A1 (ja) 2009-03-05
EP2559693A1 (en) 2013-02-20
KR20100055456A (ko) 2010-05-26
CN101815713A (zh) 2010-08-25
US20110009619A1 (en) 2011-01-13
EP2181992A4 (en) 2011-09-14
AU2008292390A1 (en) 2009-03-05
AU2008292390B2 (en) 2013-04-04
JPWO2009028588A1 (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
UY30500A1 (es) Compuestos de azabencimidazolilo
UY31189A1 (es) Compuestos heterocíclicos
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
UY30282A1 (es) Compuestos quimicos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
DK2150530T3 (da) Substituerede sulfonamid-derivater
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31141A1 (es) Compuestos de piperidina y sus usos
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien